175 million yuan Xinlitai introduced GLP-1/GCGR dual target agonist to join the new track of hypoglycemic

On September 22, Xinlitai announced that it has reached a cooperation with South Korea's D&DPharmatech, Inc.

DD01 is a long-acting GLP-1R/GCGR dual agonist developed by D&D.

DD01 is a specific dual-target agonist, which selectively activates GLP-1 (glucagon-like peptide-1) receptor and GCGR (glucagon receptor) receptor, stimulates downstream pathways, produces lower blood sugar, Reduce body weight, reduce liver fat, reduce serum cholesterol and improve liver function and other biological effects

DD01 Phase I clinical study details (Insight)

From: Insight database (http://db.

The specific financial terms of the transaction are as follows:

(1) After the agreement takes effect, the company will pay US$4 million;

(2) According to the domestic R&D and registration progress of the product, the company pays D&D the milestone payment according to the milestone, and the total amount does not exceed 23 million US dollars

(3) If the product is sold in mainland China, if the annual net sales of the product reaches the agreed amount for the first time, the company will pay the sales milestone

(4) Payment method and source of funds: cash, the source of funds is the company's self-raised funds

China has the largest number of diabetic patients

Globally, Eli Lilly’s GLP-1/GIP dual target agonist Tirzepatide has made the fastest progress, and has successively defeated semaglutide, insulin deglubber and insulin glargine in 5 registered phase III clinical trials

In addition, Dongyang Sunshine, Hengrui Medicine, and Huadong Medicine have all laid out in this field, and are currently in the early stages of research and development